Cerenkov-emission based nanosensors to detect biologic activities in vivo

基于切伦科夫发射的纳米传感器检测体内生物活性

• 批准号: 8441561
• 负责人: Jan Grimm
• 金额: $ 38.81万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-04-01 至 2016-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8441561
• 关键词: Animals; Biocompatible Coated Materials; Biological; Cadmium; Cathepsins B; Cell physiology; Cells; Charge; Clinical; Contrast Media; Copper; Coupled; Data; Dextrans; Disease; Early Diagnosis; Electrons; Enzymes; Event; Fluorochrome; Funding; Gelatinase A; Generations; Goals; Gold; Heavy Metals; Histology; Image; Inflammation; Knowledge; Life; Light; Lipids; Magnetic Resonance; Magnetic Resonance Imaging; Malignant Neoplasms; Measures; Mediating; Medicine; Methodology; Methods; Modality; Molecular; Monitor; Normal Cell; Nuclear; Optics; Outcome Study; Particulate; Peptide Hydrolases; Peptides; Physical activity; Positron; Positron-Emission Tomography; Process; Proteins; Quantum Dots; Radio; Radioactive; Radioactivity; Radioisotopes; Reading; Refractive Indices; Relative (related person); Research; Signal Transduction; Silicon Dioxide; Site; Speed; System; Technology; Testing; Time; Tissues; Toxic effect; Travel; United States National Institutes of Health; Urokinase; Water; Work; Zirconium; attenuation; base; clinical application; design; dextran; improved; in vivo; inhibitor/antagonist; innovation; intraoperative imaging; iron oxide; luminescence; molecular imaging; nanoparticle; nanosensors; optical imaging; particle; pre-clinical; radiotracer; response; tool; tumor; uptake; zirconium oxide

DESCRIPTION (provided by applicant): Activatable optical and magnetic resonance contrast agents have been devised to sense and visualize molecular activity in vivo. However, though highly sensitive, nuclear imaging has been limited considerably in sensing biological activities by the physical inability to switch radioactivity "on" or "off". To fill this gap, we hypothesize that Cerenkov luminescence imaging in conjunction with nanoparticles can be utilized to create activatable nanosensors based on radioactive decay. Blue Cerenkov light is generated by the passage of particulate radioactive emissions (such as positrons or electrons) through tissues. Cerenkov light allows for optical imaging of radiotracers with highly sensitive cameras. Based on the results of our previously demonstrated in vivo Cerenkov luminescence imaging from radiotracers, the overall objective of this application is to sense enzymatic activities associated with cancer in vivo using radiometals and modified nanoparticles In this new R01 application, cancer-related endoproteases modulate the physical interaction between different nanoparticles and a radiometals as Cerenkov emitters. Our hypothesis will be tested in three specific aims on the basis of strong preliminary data from our lab: in Specific Aim (1), we will explore different design principles of the nanoparticles in evaluating the efect of diferent coatings and radiometals onto the Cerenkov emission; in Specific Aim (2), we will sense the enzymatic activity of specific endoproteases (matrix metalloproteinase-2, cathepsin B and urokinase-type plasminogen activator) in vivo using Cerenkov imaging; in Specific Aim (3), the objective is to implement a process to quantify the nanosensor's activation and thus the enzymatic activity. This is based on a combination of Cerenkov imaging with positron emission tomography (PET) imaging. PET imaging allows for an independent quantification of the nanosensors in the tumor (using the Specific Uptake Value (SUV)) irrespective of their current activation state. We propose an inherent method to correct for the tissue attenuation and to perform a relative quantification of the signal and thus enzymatic activity. We believe that the proposed research constitutes an innovative direction and a paradigm shift in molecular imaging as it allows for sensing of enzymatic activity with radiotracers with an optical read-out, combining the unique sensitivity of PET and optical imaging together. The contribution of the proposed research is significant as it expands the potential application for nuclear imaging. It provides an entire new path for radiotracers to detect relevant biological signals. These nanosensors could ultimately find their way into the clinical realm, for example in intraoperative imaging.

描述（由申请人提供）：可激活的光学和磁共振造影剂已被设计用于感测和可视化体内分子活性。然而，尽管核成像具有高度灵敏度，但在感测生物活性方面受到相当大的限制， 物理上无法“打开”或“关闭”放射性。为了填补这一空白，我们假设， 切伦科夫发光成像结合纳米粒子可以用来创建基于放射性衰变的可激活的纳米传感器。蓝色切伦科夫光是由放射性微粒（如正电子或电子）通过组织产生的。切伦科夫光允许用高灵敏度相机对放射性示踪剂进行光学成像。基于我们先前展示的来自放射性示踪剂的体内切伦科夫发光成像的结果，本申请的总体目标是感测与放射性示踪剂相关的酶活性。 使用放射性金属和修饰的纳米颗粒在体内与癌症在这个新的R 01应用中，癌症相关的内切蛋白酶调节不同的纳米颗粒和作为切伦科夫发射体的放射性金属之间的物理相互作用。我们的假设将在三个具体目标中进行测试，基于我们实验室的初步数据：在具体目标（1）中，我们将探索纳米颗粒的不同设计原则，以评估不同涂层和放射性金属对切伦科夫发射的影响;在特异性目的（2）中，我们将检测特异性内切蛋白酶的酶活性（基质金属蛋白酶-2、组织蛋白酶B和尿激酶型纤溶酶原激活物）;在具体目标（3）中，目的是实施一种方法来量化纳米传感器的激活，从而量化酶活性。这是基于切伦科夫成像与正电子发射断层扫描（PET）成像的组合。PET成像允许对肿瘤中的纳米传感器进行独立量化（使用特定摄取值（SUV）），而不管它们当前的激活状态如何。我们提出了一种固有的方法来校正组织衰减，并执行信号的相对定量，从而酶活性。我们认为，拟议的研究构成了一个创新的方向和分子成像的范式转变，因为它允许用放射性示踪剂与光学读出传感酶活性，结合PET和光学成像的独特灵敏度在一起。这项研究的贡献是显著的，因为它扩大了核成像的潜在应用。它为放射性示踪剂检测相关生物信号提供了一条全新的途径。这些纳米传感器最终可以进入临床领域，例如术中成像。